India's Innovation Gap: From Distribution to Deep Tech

India's Startup Ecosystem: A Distribution Machine, Not an Innovation Engine

India's startup story is a remarkable case of scale. From under 500 recognized startups in 2016 to over 200,000 today, the ecosystem has attracted over $160 billion in venture capital. But a closer look reveals a critical structural weakness: the vast majority of this capital funded distribution—taking existing technologies and delivering them to a billion people faster and cheaper. This is not innovation on a global scale. As Shubham Jhuria, Cofounder & CFO of Aeravti Ventures, puts it: 'India has built a very prominent distribution ecosystem.'

The next chapter of India's growth will not be written by more startups delivering existing products faster. It will be written by founders who create something the world has never seen before. This requires a shift from a startup ecosystem to an innovation ecosystem—one that produces fundamental new technologies, scientific breakthroughs, and intellectual property that the rest of the world seeks to adopt.

The Numbers Behind the Gap

In 2023, only 5% of Indian startup funding went into deeptech sectors. By 2025, that number climbed to roughly 21%—a meaningful shift, but still far behind China, where deeptech captured 38% of all VC funding in 2024, up from just 10% in 2017. India's R&D spending as a share of GDP stands at roughly 0.64%, against China's 2.68% and the United States' 3.47%. The private sector contributes just 36% of that already-thin number; in the US and China, private R&D contributions exceed 70%.

These are not incidental gaps. They are structural ones. They reflect a decade of systematically underfunding the hardest problems. The result: India has become a net importer of technology, not a net exporter of invention.

Where the Opportunity Lies: Synthetic Biology and Climate Tech

Consider where the world is headed. Climate technology, synthetic biology, and advanced materials are not just sectors—they are civilisational bets. No country has yet established a decisive, compounding lead in any of them. That is unusual. In semiconductors, the US and Taiwan have a multi-decade head start. In AI, concentration is already visible. But in the emerging biology-driven economy and in climate infrastructure, the field is still open.

India's bioeconomy has grown from $10 billion in 2014 to over $165 billion in 2024, and is expected to grow to $300 billion by 2030. India is the pharmacy of the world, the largest vaccine producer globally, and home to a growing network of research institutions. Synthetic biology—engineering biological systems to produce materials, medicines, and fuels—is a field where India's combination of scientific talent, cost advantage, and manufacturing base could translate into real global leadership. The government's BioE3 policy, launched in 2024, the creation of a National Biofoundry Network, and the consistent efforts by BIRAC, ICMR, biotech incubators, and deeptech grants are early, encouraging signals.

Climate technology tells a similar story. India will be among the most consequential climate markets of the next thirty years, both as a country facing severe climate exposure and as one that needs to build enormous clean energy, water, and food infrastructure to serve a population approaching 1.6 billion. As Jhuria notes, 'The solutions to India's climate constraints, if they work here, will work everywhere.' That is a powerful innovation platform—but only if Indian startups are building the technology, not just deploying imported versions of it.

The Role of Patient Capital

Venture capital will play a critical role in enabling this transition. Patient capital—capital willing to wait five to ten years for technologies to mature—must become far more available to deep-tech founders. That requires different fund structures, different return expectations, and a broader acceptance that breakthrough innovation often follows timelines that do not fit traditional venture models.

The government has begun to move in the right direction. The Startup India Fund of Funds has deployed over Rs 21,000 crore into startups since 2016, and the Union Budget 2025 followed with a fresh Rs 10,000 crore FoF 2.0, with a carve out for deeptech and advanced manufacturing. These are the right moves, and they need to be expanded, not just executed. As Jhuria warns, 'Patient capital at scale only works if the funds it backs are genuinely willing to take technology risk, not just back safer bets wearing a deeptech label.'

Who Gains, Who Loses

Winners: Deeptech startups, especially in synthetic biology and climate tech, stand to gain from increased funding and government support. The bioeconomy companies are poised for explosive growth. Venture capital firms that pivot to patient capital structures will capture the next wave of value creation.

Losers: Traditional low-tech startups may see reduced capital availability as the focus shifts to deeptech. China and the US, which have invested heavily in R&D, could see their relative advantage erode if India successfully builds an innovation ecosystem.

The Bottom Line

India has already built remarkable infrastructure for helping ideas scale. The harder and more consequential task now is creating the conditions for breakthrough ideas to originate here. In many of the defining sectors of the next two decades—from synthetic biology to climate technology—the global competitive landscape remains open. No country has yet established an insurmountable lead.

That window of opportunity will not remain open indefinitely. The choice before India is whether it becomes a nation that adopts the technologies of the future, or one that invents them. For executives and investors, the signal is clear: the next decade will reward those who back deep-tech innovation with patient capital and long-term vision.

Source: YourStory